Chinese internet and mobile services firm Tencent (0700.HK) recently announced a new AI medical imaging product for medical applications, called AI Medical Innovation System (AIMIS) ("Miying" in Chinese).
AIMIS includes six artificial intelligence systems covering different diseases, including esophageal cancer, lung cancer, diabetic retinopathy, cervical cancer and breast cancer. Of these systems, Tencent's early-stage esophageal cancer screening system has already entered the pre-clinical testing stage and has a reported accuracy rate of 90%. The system has been undergoing trials in Shenzhen's Nanshan District People's Hospital for over one month and provides screening services for dozens of patients every day.
Tencent also announced that it has set up an artificial intelligence medical screening joint laboratory and initiated clinical pre-testing for its esophageal cancer early screening program in partnership with Guangdong Second People's Hospital and Nanshan District People's Hospital.